Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novelos Therapeutics has initiated Phase 1-2 positron emission tomography (PET) imaging trial of I-124-CLR1404 (LIGHT) in patients with advanced non-small cell lung cancer (NSCLC).
Subscribe to our email newsletter
LIGHT is a small molecule imaging agent that is believed to have potential for selective detection of tumors and metastases in a range of cancers.
LIGHT is comprised of a small, non-pharmacological quantity of CLR1404 (COLD, acting as a cancer-targeted delivery and retention vehicle) labeled with the short-lived radioisotope, iodine-124, a new PET imaging isotope.
Novelos president and CEO Harry Palmin said the company looks forward to obtaining initial LIGHT imaging data in the second quarter of 2012 in lung cancer patients.